Tilray Brands (TLRY) reported $915M in revenue for fiscal 2025, +11.5% year on year. That ranks #1829 by revenue among 2853 SEC filers and #167 in Healthcare. It posted a net loss of −$121M for the same year. Revenue has grown 60.9% a year on average since 2016 ($12.6M then). The fiscal 2025 balance sheet shows $2.1B in total assets, $222M in cash and $152M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $915M | +11.5% | FY20252026-05-31 |
| Gross profitGrossProfit | $260M | +8.3% | FY20252026-05-31 |
| Operating incomeOperatingIncomeLoss | −$63.0M | +$2.2B | FY20252026-05-31 |
| Net incomeNetIncomeLoss | −$121M | +$2.1B | FY20252026-05-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$69.1M | +$25.5M | FY20252026-05-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $32.9M | +12.5% | FY20242025-05-31 |
| Total assetsAssets | $2.1B | −39.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.5B | −44.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $222M | +10.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $152M | +1,509.6% | FY20212021-11-30 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-02-28 | $207M | −$26.6M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Tilray Brands, Inc.
- Ticker
- TLRY
- Exchange
- Nasdaq
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 05-31
- CIK
- 0001731348
Filings
- 10-KJul 28, 2026Open filing →
- 10-QApr 1, 2026Open filing →
- 10-QJan 8, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Pennant GroupPNTG | $948M | $29.6M |
| Ionis PharmaceuticalsIONS | $944M | −$381M |
| Usana Health SciencesUSNA | $925M | $10.8M |
| Tilray BrandsTLRY | $915M | −$121M |
| Inspire Medical SystemsINSP | $912M | $145M |
| Ani PharmaceuticalsANIP | $883M | $78.0M |
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Tilray Brands — Key figures |url=https://companiesranked.com/en/company/tilray-brands |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Tilray Brands — Key figures. CompaniesRanked. https://companiesranked.com/en/company/tilray-brandsBibTeX
@misc{companiesranked-en-company-tilray-brands-2026,
author = {{CompaniesRanked}},
title = {{Tilray Brands — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/tilray-brands}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001437749-26-024698 · July 28, 2026
{{cite web |title=Tilray Brands — Key figures — 10-K (0001437749-26-024698) |url=https://www.sec.gov/Archives/edgar/data/1731348/000143774926024698/tlry20260531_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-28}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.